The Gut–Catecholamine Connection in POTS: How HPHPA May Disrupt Norepinephrine, Vascular Tone, and Methylation

One pattern I have been paying much closer attention to in people with POTS, dysautonomia, gastrointestinal dysfunction, and post-infectious illness is the possibility that the cardiovascular phenotype may sometimes begin much further upstream than the heart.

In one particularly interesting case, a client had orthostatic tachycardia and blood pooling together with markedly elevated 3-(3-hydroxyphenyl)-3-hydroxypropionic acid, or HPHPA. At the same time, the catecholamine-metabolite pattern appeared disproportionately shifted toward dopamine-derived metabolism relative to norepinephrine-derived metabolism. That combination made me look much more closely at the biochemical junction between dopamine and norepinephrine.

Norepinephrine is one of the principal neurotransmitters the sympathetic nervous system uses to maintain vascular tone when we stand. If effective norepinephrine production or release becomes inadequate, the resulting tachycardia may sometimes represent compensation for insufficient vascular constriction rather than the primary abnormality itself. That creates a very different way of thinking about at least one possible POTS phenotype.

HPHPA is associated with altered microbial metabolism of aromatic amino acids related to phenylalanine and tyrosine pathways. These amino acids sit at an important intersection between microbial metabolism and human catecholamine biology. In the host, phenylalanine contributes to tyrosine availability, tyrosine is converted toward L-DOPA and dopamine, and dopamine can subsequently be converted into norepinephrine by dopamine beta-hydroxylase, or DBH.

DBH therefore occupies a strategically important position in autonomic physiology. It is a copper-dependent monooxygenase located within catecholamine storage vesicles in central noradrenergic neurons and peripheral sympathetic nerve terminals. Its catalytic function depends on copper, molecular oxygen, ascorbate, appropriate copper redox cycling, and the structural integrity of the enzyme.

Ascorbate is especially important because it is not functioning merely as a generic antioxidant. It participates directly in the electron-transfer chemistry that allows the copper centers within DBH to cycle through the redox states required for dopamine hydroxylation. Copper and vitamin C therefore sit directly inside the biochemical machinery responsible for norepinephrine synthesis.

This makes DBH an interesting point of convergence between micronutrient status, redox biology, microbial metabolism, catecholamine chemistry, and autonomic physiology.

Elevated urinary HPHPA does not prove that HPHPA is directly binding the copper centers of DBH inside human sympathetic neurons, and I would not interpret it that way. The more defensible hypothesis is that sufficiently high exposure to HPHPA or related microbial phenolic metabolites could alter DBH activity directly or indirectly through effects on copper-dependent catalysis, redox chemistry, enzyme structure, cofactor availability, or the surrounding metabolic environment.

If DBH activity becomes relatively constrained, less dopamine may be converted into norepinephrine. The dopamine that does not enter norepinephrine synthesis still has to be stored, recycled, or metabolized. One major disposal pathway involves monoamine oxidase, which metabolizes dopamine through DOPAL toward DOPAC. DOPAC can then undergo methylation involving catechol-O-methyltransferase, or COMT, contributing to formation of homovanillic acid, HVA.

Conceptually, this creates a potential catecholamine shunt. Instead of dopamine flux moving efficiently toward norepinephrine, a greater proportion of that flux may be redirected toward dopamine degradation and clearance.

This becomes particularly interesting when the relative distribution of dopamine- and norepinephrine-derived metabolites shifts. Urinary HVA, DOPAC, and VMA should not be treated as direct diagnostic tests for DBH dysfunction because they are influenced by multiple tissues, renal handling, diet, medications, enzyme activity, and overall catecholamine turnover. But when the metabolite pattern aligns with the orthostatic physiology, it can generate a useful mechanistic hypothesis.

The pathway becomes even more important once methylation is considered.

COMT is a methyltransferase. It uses S-adenosylmethionine, SAM, as its methyl donor and generates S-adenosylhomocysteine, SAH, after transferring that methyl group. This means increased catecholamine clearance through COMT has a real metabolic cost. Greater COMT flux means greater methyl-group demand and greater production of SAH.

SAH is not simply an inactive waste product. It is a potent product inhibitor of many SAM-dependent methyltransferases. This changes how methylation should be interpreted. A person can have adequate SAM while still having impaired effective methylation if SAH is disproportionately elevated. The relationship between SAM and SAH can therefore be more informative than looking at SAM in isolation.

If dopamine-to-norepinephrine throughput becomes relatively constrained, more dopamine may require disposal through MAO-associated metabolism. More catechol substrate may subsequently require COMT-dependent methylation. COMT consumes additional SAM, SAH production increases, and the SAM-to-SAH ratio can begin to deteriorate.

If SAH accumulates sufficiently, it can begin inhibiting the same methyltransferases responsible for handling the increased substrate load. That creates the possibility of a metabolic feedback problem in which increasing catecholamine clearance generates increasing SAH, while increasing SAH progressively reduces methylation potential.

This is why simply adding more SAMe may not always solve a low-methylation phenotype. If the underlying problem is excessive SAH generation or inadequate SAH clearance, supplying additional methyl donor may increase flux temporarily without correcting the bottleneck.

Another pathway may contribute to the same methylation pressure: the relationship between CD38, NAD metabolism, nicotinamide, and NNMT.

CD38 is an NAD-metabolizing enzyme whose expression and activity can increase substantially in inflammatory environments. Microbial products such as lipopolysaccharide, inflammatory cytokines, and cellular damage signals can activate innate immune pathways involving Toll-like receptors, NF-kappaB, JAK/STAT, P2X7, RAGE, and related signaling systems. One downstream consequence can be increased CD38 expression.

Increased CD38 activity can contribute to accelerated NAD turnover and increased generation of nicotinamide, NAM. Nicotinamide then has to be recycled, metabolized, or eliminated. One route involves nicotinamide N-methyltransferase, NNMT, which uses SAM to methylate nicotinamide into 1-methylnicotinamide while generating SAH.

This creates another direct connection to the methyl pool. COMT consumes SAM and produces SAH while handling catechols. NNMT consumes SAM and produces SAH while handling nicotinamide. If inflammatory NAD turnover and catecholamine turnover are simultaneously elevated, both systems may converge on the same methylation economy.

This becomes particularly relevant when considering NAD precursors such as NMN. The issue is not that NMN is inherently harmful or that supplementation necessarily increases SAH. The important variable is metabolic context. If inflammatory NAD turnover is already accelerated, increasing precursor availability may not necessarily translate proportionally into a larger stable intracellular NAD pool. Some of that increased flux may ultimately increase nicotinamide handling. If NNMT participates substantially in disposing of that nicotinamide, methyl-group demand could increase.

A third major methyl sink is endogenous creatine synthesis. Guanidinoacetate methyltransferase, GAMT, uses SAM to methylate guanidinoacetate and produce creatine. Endogenous creatine synthesis represents a substantial component of whole-body methyl-group demand.

This means GAMT, COMT, and NNMT can all draw from the same SAM pool while generating SAH. That is one reason exogenous creatine can be metabolically interesting beyond muscle performance. Providing creatine directly can suppress endogenous creatine synthesis, potentially reducing part of the methyl-group demand through GAMT.

The larger point is that methylation should be thought about as flux through a shared metabolic economy rather than as an isolated “methylation pathway.” The relevant question is not simply how much SAM is present. It is how rapidly SAM is being consumed, which enzymes are consuming it, how much SAH those reactions are generating, and whether SAH can be removed rapidly enough to preserve methyltransferase activity.

SAH clearance is therefore just as important as SAM supply.

S-adenosylhomocysteine hydrolase, AHCY, catalyzes the reversible interconversion of SAH with homocysteine and adenosine. The reversibility of this reaction is critical. Efficient SAH disposal depends on the downstream removal of homocysteine and adenosine. Homocysteine can be remethylated toward methionine or diverted into transsulfuration, while adenosine is metabolized or transported through other pathways.

This is why homocysteine cannot always be interpreted using the simplistic assumption that lower is necessarily better. Concentration and flux are not the same thing.

Transsulfuration becomes relevant here because homocysteine can enter the cystathionine pathway through cystathionine beta-synthase, CBS. CBS and downstream cystathionine gamma-lyase depend on pyridoxal-5’-phosphate, the active form of vitamin B6. Adequate P5P therefore does not directly “clear SAH.” Rather, it supports one of the downstream pathways that handles homocysteine and can help preserve the metabolic pull required for continued SAH clearance.

This connects methylation with sulfur metabolism, cysteine availability, glutathione biology, and ultimately cellular redox capacity.

There is another reason sulfur metabolism matters in this model. Phenolic microbial metabolites absorbed across the intestine have to be conjugated and eliminated. Sulfation is one of the important Phase II pathways involved in handling many phenolic compounds.

Sulfotransferase enzymes do not attach free sulfate directly to substrates. They use the activated sulfate donor PAPS, or 3’-phosphoadenosine-5’-phosphosulfate. PAPS has to be synthesized, and its synthesis requires ATP.

That means phenolic clearance depends not only on microbial production but also on host capacity: sulfate availability, ATP production, PAPS synthesis, sulfotransferase activity, competing substrates, hepatic function, renal elimination, and overall metabolic state.

This changes how a high urinary microbial metabolite such as HPHPA should be interpreted. A high concentration does not automatically mean that one organism is simply “overgrown.” The measured value represents the net result of microbial production, intestinal absorption, barrier permeability, hepatic metabolism, conjugation, tissue distribution, and renal excretion. Two people could produce similar amounts of a microbial metabolite and show very different systemic exposure depending on their host capacity to contain and clear it.

Returning to DBH adds another layer to the model. Because DBH depends directly on copper and ascorbate, the functional state of this enzyme may influence not only norepinephrine production but also the downstream methylation burden created by dopamine disposal.

If DBH function improves and more dopamine can be efficiently converted into norepinephrine, less dopamine may need to be routed toward MAO-associated degradation and COMT-dependent methylation. In principle, that could reduce catechol substrate pressure on COMT, reduce SAM consumption, and reduce one source of SAH generation.

This does not mean that copper or vitamin C should automatically be given to people with POTS, elevated HPHPA, or abnormal catecholamine metabolites. Copper biology is tightly regulated. Serum copper, ceruloplasmin, zinc exposure, dietary copper, hepatic function, inflammatory status, and redox balance all influence interpretation. Excess copper can be harmful just as inadequate copper can impair copper-dependent enzymes.

Vitamin C also participates directly in catecholamine and metal-redox chemistry. The relevant concept is not indiscriminate supplementation. It is determining whether the DBH system has the cofactors and biochemical environment required to function appropriately.

The cardiovascular relevance becomes clearer when the physiology of standing is considered.

When a person stands, gravity redistributes a substantial volume of blood toward the lower extremities and splanchnic circulation. The body must compensate rapidly to preserve venous return, ventricular filling, stroke volume, cerebral perfusion, and arterial pressure.

Baroreflex activation increases sympathetic output. Peripheral sympathetic nerve terminals release norepinephrine, which activates alpha-adrenergic receptors on vascular smooth muscle and increases vascular tone. This constriction limits excessive pooling and helps return blood toward the heart.

If effective peripheral norepinephrine production or release becomes inadequate, vascular constriction may be insufficient. More blood remains in the lower-body capacitance circulation, venous return decreases, ventricular filling falls, and stroke volume declines.

Cardiac output is determined by heart rate multiplied by stroke volume. If stroke volume falls, increasing heart rate becomes one of the body’s available compensatory mechanisms for maintaining cardiac output.

This distinction matters enormously in POTS.

In some patients, tachycardia may not be the initiating defect. The heart may be accelerating because vascular compensation is inadequate. The visible phenotype is tachycardia, but the upstream problem may reside in blood volume, venous capacitance, sympathetic innervation, vascular receptors, endothelial biology, catecholamine synthesis, or some combination of these systems.

This is why dopamine-to-norepinephrine metabolism becomes potentially relevant. If DBH throughput is impaired enough to reduce functional norepinephrine availability at peripheral sympathetic terminals, alpha-adrenergic vasoconstriction could become less effective. Blood pooling would increase, venous return and stroke volume would decline, and compensatory tachycardia could become more pronounced.

The same upstream disturbance could potentially have neurological consequences.

The locus coeruleus is the major noradrenergic nucleus of the brain and projects widely into cortical and subcortical regions. Its signaling contributes to vigilance, attention, sensory gating, arousal, salience processing, stress adaptation, and sleep-wake regulation.

A disturbance in noradrenergic physiology could therefore manifest as much more than altered vascular tone. Changes in cognitive reserve, sensory filtering, sleep architecture, vigilance, and arousal could occur alongside autonomic symptoms.

This does not mean that brain fog, light sensitivity, sound sensitivity, or sleep disturbance proves DBH dysfunction. Those symptoms have many possible mechanisms. But it demonstrates why cardiovascular and neurological manifestations of dysautonomia should not always be treated as unrelated problems.

Dopamine itself also deserves attention because it is chemically reactive. Cytosolic dopamine can undergo oxidation and generate reactive quinones and related intermediates. These compounds can interact with glutathione, protein thiols, mitochondrial proteins, redox-sensitive enzymes, and cellular stress pathways.

Dopamine-derived reactive species have been studied extensively in neuronal biology because excessive intracellular catechol oxidation can damage mitochondrial systems, including Complex I, and increase oxidative stress.

This creates a potentially important dual consequence of impaired dopamine-to-norepinephrine handling. There may be insufficient norepinephrine signaling where norepinephrine is required while simultaneously increasing the burden of dopamine metabolism and oxidation upstream.

In a susceptible host, that could potentially connect autonomic dysfunction with cognitive symptoms, sensory hypersensitivity, sleep disturbance, exercise intolerance, or post-exertional worsening.

When these pathways are integrated, a much larger systems-level model begins to emerge.

Altered intestinal microbial ecology changes aromatic amino-acid metabolism and increases production of phenolic metabolites such as HPHPA. Increased intestinal permeability or impaired mucosal containment allows greater exposure of the host to those metabolites. The liver and other tissues then have to conjugate and eliminate them, creating demands on sulfation, PAPS synthesis, ATP production, and other Phase II pathways.

If microbial metabolite production exceeds host clearance capacity, systemic exposure rises.

If HPHPA or related microbial phenolics interfere directly or indirectly with DBH function, dopamine-to-norepinephrine throughput may fall. More dopamine then requires alternative metabolism through MAO-associated pathways and COMT-dependent methylation.

Increased COMT flux consumes SAM and generates SAH.

At the same time, microbial products and inflammatory signaling may increase CD38 activity and accelerate NAD turnover. Increased nicotinamide handling through NNMT creates another SAM-consuming, SAH-generating pathway.

Endogenous creatine synthesis through GAMT adds another major methyl demand.

If SAH production begins to exceed clearance through AHCY and downstream homocysteine and adenosine metabolism, the SAM-to-SAH ratio deteriorates. As SAH accumulates, methyltransferases become progressively more vulnerable to product inhibition.

Catecholamine handling can then become increasingly difficult at exactly the time the system is demanding more catecholamine clearance.

Meanwhile, inadequate norepinephrine production or signaling can weaken sympathetic vasoconstriction. Blood pooling increases, venous return falls, stroke volume falls, and heart rate rises to compensate.

At the same time, altered dopamine handling may increase oxidative and mitochondrial stress.

The resulting phenotype could therefore emerge from interactions among microbial metabolism, intestinal barrier function, hepatic conjugation, mitochondrial energy production, NAD metabolism, methylation, catecholamine synthesis, vascular tone, and autonomic compensation.

This does not explain every case of POTS.

POTS is heterogeneous, and any model that attempts to explain every patient through one pathway is almost certainly wrong. Some patients have a hyperadrenergic phenotype with elevated standing norepinephrine, which would argue strongly against a simple systemic norepinephrine-deficiency model.

Others may have small-fiber autonomic neuropathy, hypovolemia, impaired renin-angiotensin-aldosterone responses, mast-cell activation, connective-tissue abnormalities, abnormal venous capacitance, norepinephrine-transporter dysfunction, autoimmune mechanisms, endothelial abnormalities, post-infectious autonomic injury, or several of these simultaneously.

The model described here should therefore be considered a possible subtype or contributing mechanism, not an explanation for POTS as a whole.

HPHPA alone cannot diagnose DBH inhibition. Urinary HVA cannot diagnose dopamine excess. VMA cannot establish norepinephrine deficiency. A low SAM-to-SAH ratio cannot identify which methyl-consuming pathway is responsible. Copper or vitamin C status cannot be inferred from an organic-acid profile.

The hypothesis becomes more compelling only when multiple independent observations converge on the same physiology.

The most useful question is often not simply which organisms are elevated. It is what those organisms are producing, why they are producing it, how much of those metabolites cross the intestinal barrier, whether the host can conjugate and eliminate them, whether mitochondrial ATP production can support that clearance, whether inflammatory signaling is accelerating NAD turnover, whether NNMT and COMT are creating excessive methyl demand, whether SAH is accumulating, whether DBH has the cofactors and redox environment required to function, and whether the predicted disturbance can actually be demonstrated physiologically.

A mechanistic model becomes useful only when it produces predictions that can be tested.

If impaired dopamine-to-norepinephrine conversion is contributing to a person’s orthostatic physiology, there should eventually be measurable evidence of altered catecholamine handling, vascular compensation, or both. If those predictions repeatedly fail, the model needs to be revised or rejected.

That is where POTS begins to look less like an isolated heart-rate disorder and more like what it often is: a cardiovascular phenotype emerging from interactions among the gut, immune system, metabolism, mitochondria, catecholamines, vascular biology, and the autonomic nervous system.